XPA tumor variants lead to defects in NER that sensitize cells to cisplatin https://www.biorxiv.org/content/10.1101/2023.06.29.547124v1?med=mas
XPA tumor variants lead to defects in NER that sensitize cells to cisplatin https://www.biorxiv.org/content/10.1101/2023.06.29.547124v1?med=mas